302 related articles for article (PubMed ID: 25472655)
1. Magnesium supplementation and high volume hydration reduce the renal toxicity caused by cisplatin-based chemotherapy in patients with lung cancer: a toxicity study.
Oka T; Kimura T; Suzumura T; Yoshimoto N; Nakai T; Yamamoto N; Matsuura K; Mitsuoka S; Yoshimura N; Kudoh S; Hirata K
BMC Pharmacol Toxicol; 2014 Dec; 15():70. PubMed ID: 25472655
[TBL] [Abstract][Full Text] [Related]
2. Short hydration with 20 mEq of magnesium supplementation for lung cancer patients receiving cisplatin-based chemotherapy: a prospective study.
Hase T; Miyazaki M; Ichikawa K; Yogo N; Ozawa N; Hatta T; Ando M; Sato M; Kondo M; Yamada K; Hasegawa Y
Int J Clin Oncol; 2020 Nov; 25(11):1928-1935. PubMed ID: 32740717
[TBL] [Abstract][Full Text] [Related]
3. Short hydration in chemotherapy containing cisplatin (≥75 mg/m2) for patients with lung cancer: a prospective study.
Horinouchi H; Kubota K; Itani H; Taniyama TK; Nakamichi S; Wakui H; Kanda S; Nokihara H; Yamamoto N; Sekine I; Tamura T
Jpn J Clin Oncol; 2013 Nov; 43(11):1105-9. PubMed ID: 24006505
[TBL] [Abstract][Full Text] [Related]
4. Hydration with 15 mEq Magnesium Is Effective at Reducingthe Risk for Cisplatin-induced Nephrotoxicity in Patients Receiving Cisplatin (≥50 mg/m2) Combination Chemotherapy.
Yamamoto Y; Watanabe K; Tsukiyama I; Yabushita H; Matsuura K; Wakatsuki A
Anticancer Res; 2016 Apr; 36(4):1873-7. PubMed ID: 27069173
[TBL] [Abstract][Full Text] [Related]
5. Short hydration regimen with magnesium supplementation prevents cisplatin-induced nephrotoxicity in lung cancer: a retrospective analysis.
Yamaguchi T; Uozu S; Isogai S; Hayashi M; Goto Y; Nakanishi T; Imaizumi K
Support Care Cancer; 2017 Apr; 25(4):1215-1220. PubMed ID: 27966021
[TBL] [Abstract][Full Text] [Related]
6. Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung cancer in the Okayama Lung Cancer Study Group Trial 1002.
Hotta K; Takigawa N; Hisamoto-Sato A; Ichihara E; Kudo K; Uchida K; Yanase-Nakamura K; Tanaka H; Kato Y; Tabata M; Tanimoto M; Kiura K
Jpn J Clin Oncol; 2013 Nov; 43(11):1115-23. PubMed ID: 24082005
[TBL] [Abstract][Full Text] [Related]
7. [Feasibility of short volume hydration in patients with lung cancer treated with Cisplatin-containing chemotherapy].
Ohhara Y; Isobe H; Ito K; Fuke S; Kojima T; Saito H; Nishiura Y
Gan To Kagaku Ryoho; 2015 Jan; 42(1):57-61. PubMed ID: 25596680
[TBL] [Abstract][Full Text] [Related]
8. Safety of a short hydration method for cisplatin administration in comparison with a conventional method-a retrospective study.
Sakaida E; Iwasawa S; Kurimoto R; Ebata T; Imai C; Oku T; Sekine I; Tada Y; Tatsumi K; Takiguchi Y
Jpn J Clin Oncol; 2016 Apr; 46(4):370-7. PubMed ID: 26755829
[TBL] [Abstract][Full Text] [Related]
9. Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201.
Ninomiya K; Hotta K; Hisamoto-Sato A; Ichihara E; Gotoda H; Morichika D; Tamura T; Kayatani H; Minami D; Kubo T; Tabata M; Tanimoto M; Kiura K
Int J Clin Oncol; 2016 Feb; 21(1):81-7. PubMed ID: 26093520
[TBL] [Abstract][Full Text] [Related]
10. Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer.
Raj GV; Iasonos A; Herr H; Donat SM
J Clin Oncol; 2006 Jul; 24(19):3095-100. PubMed ID: 16809735
[TBL] [Abstract][Full Text] [Related]
11. Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma.
Tiseo M; Martelli O; Mancuso A; Sormani MP; Bruzzi P; Di Salvia R; De Marinis F; Ardizzoni A
Tumori; 2007; 93(2):138-44. PubMed ID: 17557559
[TBL] [Abstract][Full Text] [Related]
12. Risk Factors Associated with Cisplatin-Induced Nephrotoxicity in Patients with Advanced Lung Cancer.
Miyoshi T; Misumi N; Hiraike M; Mihara Y; Nishino T; Tsuruta M; Kawamata Y; Hiraki Y; Kozono A; Ichiki M
Biol Pharm Bull; 2016; 39(12):2009-2014. PubMed ID: 27904042
[TBL] [Abstract][Full Text] [Related]
13. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial.
Santoso JT; Lucci JA; Coleman RL; Schafer I; Hannigan EV
Cancer Chemother Pharmacol; 2003 Jul; 52(1):13-8. PubMed ID: 12719883
[TBL] [Abstract][Full Text] [Related]
14. Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy.
McKibbin T; Cheng LL; Kim S; Steuer CE; Owonikoko TK; Khuri FR; Shin DM; Saba NF
Support Care Cancer; 2016 Apr; 24(4):1789-93. PubMed ID: 26446698
[TBL] [Abstract][Full Text] [Related]
15. Hydration regimen and hematological toxicity of a cisplatin-based chemotherapy regimen. Clinical observations and pharmacokinetic analysis.
Numico G; Benasso M; Vannozzi MO; Merlano M; Rosso R; Viale M; Esposito M
Anticancer Res; 1998; 18(2B):1313-8. PubMed ID: 9615808
[TBL] [Abstract][Full Text] [Related]
16. Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study.
Bodnar L; Wcislo G; Gasowska-Bodnar A; Synowiec A; Szarlej-Wcisło K; Szczylik C
Eur J Cancer; 2008 Nov; 44(17):2608-14. PubMed ID: 18796350
[TBL] [Abstract][Full Text] [Related]
17. Difference in decline in renal function due to cisplatin after a short or long hydration scheme in non-small-cell lung cancer: A retrospective cohort study (HYCIS-XL).
Niggebrugge-Mentink KL; Beex-Oosterhuis MM; Ter Horst PGJ; van de Poll MEC; Dieleman HG; van Kesteren C
J Clin Pharm Ther; 2020 Oct; 45(5):1153-1158. PubMed ID: 32533904
[TBL] [Abstract][Full Text] [Related]
18. A retrospective evaluation of furosemide and mannitol for prevention of cisplatin-induced nephrotoxicity.
Mach CM; Kha C; Nguyen D; Shumway J; Meaders KM; Ludwig M; Williams-Brown MY; Anderson ML
J Clin Pharm Ther; 2017 Jun; 42(3):286-291. PubMed ID: 28276070
[TBL] [Abstract][Full Text] [Related]
19. Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: which dose is more suitable?
Ilhan Y; Onder AH; Ozbay MF; Karakaya G; Sezgin Goksu S; Ozturk B; Coskun HS
Eur Rev Med Pharmacol Sci; 2024 May; 28(9):3403-3413. PubMed ID: 38766796
[TBL] [Abstract][Full Text] [Related]
20. Incidence of Severe Nephrotoxicity With Cisplatin Based on Renal Function Eligibility Criteria: Indirect Comparison Meta-analysis.
Dahal A; Bellows BK; Sonpavde G; Tantravahi SK; Choueiri TK; Galsky MD; Agarwal N
Am J Clin Oncol; 2016 Oct; 39(5):497-506. PubMed ID: 24824144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]